(Q54560801)

31 May 2018

retracted paper

2 references

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab. (English)

1 reference

31 May 2018

0 references

1 reference

Roman Perez-Soler

1

1 reference

31 May 2018

Yiyu Zou

series ordinal

2

1 reference

31 May 2018

Tianhong Li

series ordinal

3

1 reference

31 May 2018

Yi He Ling

series ordinal

4

1 reference

31 May 2018

language of work or name

English

0 references

publication date

13 September 2011

1 reference

31 May 2018

published in

Clinical Cancer Research

1 reference

31 May 2018

volume

17

1 reference

31 May 2018

issue

21

1 reference

31 May 2018

page(s)

6766-6777

1 reference

31 May 2018

Retraction: The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab

is retracted by

0 references

cites work

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Cutaneous lesions in the rat following administration of an irreversible inhibitor of erbB receptors, including the epidermal growth factor receptor

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Retraction: The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

EGFR activation coupled to inhibition of tyrosine phosphatases causes lateral signal propagation

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Targeting protein serine/threonine phosphatases for drug development

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Menadione induces both necrosis and apoptosis in rat pancreatic acinar AR4-2J cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Skin toxicity caused by EGFR antagonists-an autoinflammatory condition triggered by deregulated IL-1 signaling?

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

EGFR regulates the expression of keratinocyte-derived granulocyte/macrophage colony-stimulating factor in vitro and in vivo

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

HaCaT keratinocyte migration is dependent on epidermal growth factor receptor signaling and glycogen synthase kinase-3alpha

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Negative regulation of EGFR signalling through integrin-alpha1beta1-mediated activation of protein tyrosine phosphatase TCPTP

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

ERK1/2 regulates epidermal chemokine expression and skin inflammation

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Erlotinib in previously treated non-small-cell lung cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Endogenous EGF-family growth factors are necessary for the progression from the G1 to S phase in human keratinocytes

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Receptor type protein tyrosine phosphatase-kappa mediates cross-talk between transforming growth factor-beta and epidermal growth factor receptor signaling pathways in human keratinocytes

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Reactive oxygen species and insulin resistance: the good, the bad and the ugly

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Drug discovery and protein tyrosine phosphatases.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Tetracyclines: nonantibiotic properties and their clinical implications

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Skin toxicities associated with epidermal growth factor receptor inhibitors

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Serine/threonine phosphatases in the DNA damage response and cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Epidermal growth factor receptor is a common mediator of quinone-induced signaling leading to phosphorylation of connexin-43: role of glutathione and tyrosine phosphatases

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Sorafenib: a clinical and pharmacologic review

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

EGF receptor signaling inhibits keratinocyte apoptosis: evidence for mediation by Bcl-XL

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Reactive oxygen species as essential mediators of cell adhesion: the oxidative inhibition of a FAK tyrosine phosphatase is required for cell adhesion.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Regulation of receptor protein-tyrosine phosphatase alpha by oxidative stress

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

The therapeutic potential of phosphatase inhibitors

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Quinone-induced DNA single strand breaks in a human colon carcinoma cell line

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Regulation of cell proliferation by NADPH oxidase-mediated signaling: potential roles in tissue repair, regenerative medicine and tissue engineering

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Induction of dna damage by menadione (2-methyl-1,4-naphthoquinone) in primary cultures of rat hepatocytes

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Mechanisms of cutaneous toxicities to EGFR inhibitors.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-11-0545

Identifiers

DOI

10.1158/1078-0432.CCR-11-0545

1 reference

31 May 2018

1 reference

31 May 2018